Aβ-oligomers: A potential therapeutic target for Alzheimer's disease
The cascade of amyloid formation relates to multiple complex events at the molecular level.
Previous research has established amyloid plaque deposition as the leading cause of …
Previous research has established amyloid plaque deposition as the leading cause of …
Modulating protein–protein interactions: the potential of peptides
L Nevola, E Giralt - Chemical Communications, 2015 - pubs.rsc.org
Protein–protein interactions (PPIs) have emerged as important and challenging targets in
chemical biology and medicinal chemistry. The main difficulty encountered in the discovery …
chemical biology and medicinal chemistry. The main difficulty encountered in the discovery …
Rationally designed peptides and peptidomimetics as inhibitors of amyloid-β (Aβ) aggregation: Potential therapeutics of Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative disease with no clinically
accepted treatment to cure or halt its progression. The worldwide effort to develop peptide …
accepted treatment to cure or halt its progression. The worldwide effort to develop peptide …
Targeting amyloid aggregation: an overview of strategies and mechanisms
Amyloids result from the aggregation of a set of diverse proteins, due to either specific
mutations or promoting intra-or extra-cellular conditions. Structurally, they are rich in …
mutations or promoting intra-or extra-cellular conditions. Structurally, they are rich in …
Protein aggregation: from background to inhibition strategies
The aggregation of specific proteins is hypothesized to cause several pathological
conditions, which are collectively known as amyloid disorders. The aggregation of peptides …
conditions, which are collectively known as amyloid disorders. The aggregation of peptides …
Molecular insights into the inhibition of early stages of Aβ peptide aggregation and destabilization of Alzheimer's Aβ protofibril by dipeptide D-Trp-Aib: A molecular …
Amyloid beta (Aβ) peptide aggregates rapidly into the soluble oligomers, protofibrils and
fibrils to form senile plaques, a neurotoxic component and pathological hallmark of …
fibrils to form senile plaques, a neurotoxic component and pathological hallmark of …
Recent advances in the design and applications of amyloid-β peptide aggregation inhibitors for Alzheimer's disease therapy
Alzheimer's disease (AD) is an irreversible neurological disorder that progresses gradually
and can cause severe cognitive and behavioral impairments. This disease is currently …
and can cause severe cognitive and behavioral impairments. This disease is currently …
Peptides, peptidomimetics, and carbohydrate–peptide conjugates as amyloidogenic aggregation inhibitors for Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder accounting for 60–
80% of dementia cases. For many years, AD causality was attributed to amyloid-β (Aβ) …
80% of dementia cases. For many years, AD causality was attributed to amyloid-β (Aβ) …
Exploring Peptido‐Nanocomposites in the Context of Amyloid Diseases
N Andrikopoulos, H Tang, Y Wang, X Liang… - Angewandte …, 2024 - Wiley Online Library
Therapeutic peptides are a major class of pharmaceutical drugs owing to their target‐
binding specificity as well as their versatility in inhibiting aberrant protein‐protein …
binding specificity as well as their versatility in inhibiting aberrant protein‐protein …
Toward a rational design to regulate β-amyloid fibrillation for Alzheimer's disease treatment
X Han, G He - ACS chemical neuroscience, 2018 - ACS Publications
The last decades have witnessed a growing global burden of Alzheimer's disease (AD).
Evidence indicates that the onset and progression of AD is associated with β-amyloid (Aβ) …
Evidence indicates that the onset and progression of AD is associated with β-amyloid (Aβ) …